GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (FRA:PHGN) » Definitions » General and Admin. Expense

Pharming Group (FRA:PHGN) General and Admin. Expense : €93.1 Mil (TTM As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Pharming Group General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Pharming Group's General and Admin. Expense for the three months ended in Mar. 2025 was €20.8 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2025 was €93.1 Mil.

Pharming Group General and Admin. Expense Historical Data

The historical data trend for Pharming Group's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group General and Admin. Expense Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.01 41.04 58.95 73.99 87.94

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.88 14.51 13.78 44.01 20.80

Pharming Group General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €93.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Pharming Group's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (FRA:PHGN) » Definitions » General and Admin. Expense
Comparable Companies
XAMS:VVY XAMS:GLPG VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170 OCSE:GMAB INSM BMRN HKSE:02269 SHSE:603392
Traded in Other Exchanges
PHAR:USA PHGUF:USA PHARM:Netherlands 0QCO:UK
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Website
https://www.pharming.com
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines

No Headlines